CORDIS AMILA PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) BALLOON DILATATION CATHETER
K063563 · Cordis Europa, N.V. · LIT · Mar 7, 2007 · Cardiovascular
Device Facts
| Record ID | K063563 |
| Device Name | CORDIS AMILA PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) BALLOON DILATATION CATHETER |
| Applicant | Cordis Europa, N.V. |
| Product Code | LIT · Cardiovascular |
| Decision Date | Mar 7, 2007 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 870.1250 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
The Cordis AMIIA PTA Balloon Dilatation catheter is intended for Percutaneous Transluminal Angioplasty in the peripheral vasculature, including iliac, femoral, ilio-femoral, popliteal, infra popliteal, renal, and carotid arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for post-dilatation of balloon-expandable and self-expanding stents in the peripheral vasculature.
Device Story
The Cordis AMIIA PTA Balloon Dilatation Catheter is a rapid-exchange catheter featuring a distal DURALYN inflatable balloon and a tapered tip for crossing tight lesions. It includes a single inflation lumen and a distal guide wire lumen with an exit port 25 cm from the tip. Two radiopaque marker bands indicate the dilating section; proximal shaft markers indicate catheter position relative to the guiding catheter. Operated by physicians in a clinical setting, the device is inflated via a proximal hub using diluted contrast medium. The balloon expands to dilate peripheral vasculature or stents. The device facilitates lesion treatment and stent post-dilatation, potentially improving blood flow in stenotic vessels or dialysis fistulae.
Clinical Evidence
Bench testing only. No clinical data provided. Safety and effectiveness demonstrated via non-clinical design verification tests and analyses.
Technological Characteristics
Rapid exchange catheter with DURALYN inflatable balloon; single inflation lumen; distal guide wire lumen; radiopaque marker bands; tapered tip. Usable shaft length 142 cm. Operates via hydraulic inflation with contrast medium. Class II device.
Indications for Use
Indicated for patients requiring percutaneous transluminal angioplasty in peripheral arteries (iliac, femoral, ilio-femoral, popliteal, infra-popliteal, renal, carotid) or treatment of obstructive lesions in native/synthetic arteriovenous dialysis fistulae; also indicated for post-dilatation of peripheral stents.
Regulatory Classification
Identification
A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.
Predicate Devices
- Cordis AMIIA PTA Balloon Dilatation Catheter (K050645)
- Boston Scientific Sterling Monorail PTA Balloon Dilatation Catheter (K053118)
Related Devices
- K050645 — CORDIS AMIIA .014 PTA BALLOON CATHETER · Cordis Corp. · Apr 1, 2005
- K013581 — CORDIS AVIATOR PERIPHERAL DILATATION CATHETER · Cordis, A Johnson & Johnson Co. · Nov 28, 2001
- K113468 — ELM PTA BALLON DILATATION CATHETER · Creagh Medical, Ltd. · Dec 20, 2011
- K071189 — CORDIS AVIATOR PLUS PTA BALLOON DILATATION CATHETER · Cordis Europa, N.V. · May 16, 2007
- K012050 — VIATRAC 14 PLUS PERIPHERAL DILATATION CATHETER · Guidant Corp. · Sep 6, 2001
Submission Summary (Full Text)
{0}------------------------------------------------
| | | K063563<br>p. 1 of 3 | |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-------------|
| | | FDA 510(k) Notification | |
| | | Cordis AMIIA PTA Balloon Dilatation Catheter | |
| Section 3: | 510(k) Summary (21 CFR 807.92) | | MAR 07 2007 |
| Submitter &<br>Contact<br>person: | Cordis Europa, N.V.<br>Harm Hovinga, Senior Regulatory Affairs Associate<br>Oosteinde 8<br>9301 LJ Roden,<br>The Netherlands | | |
| | Tel: +31 50 50 22479<br>Fax: +31 50 50 22456<br>e-mail: hhovinga@crdnl.jnj.com | | |
| Alternate<br>Contact: | Cordis Corporation<br>Joan Martin, Manager Regulatory Affairs<br>7 Powder Horn Drive<br>Warren, NJ 07059<br>USA | | |
| | Tel: (+1) 908 412 7250<br>Fax: (+1) 908 412 3915<br>e-mail: jmartin@crdus.jnj.com | | |
| Date Prepared | November 23, 2006. | | |
| Trade Name | Cordis AMIIA™ Percutaneous Transluminal Angioplasty (PTA) Balloon<br>Dilatation Catheter. | | |
| Predicate<br>Device(s) | The predicate devices for the subject Cordis AMIIA PTA Balloon Dilatation<br>Catheter are:<br>> Cordis AMIIA PTA Balloon Dilatation Catheter, which was<br>determined substantially equivalent by FDA (ref. 510(k) number<br>#K050645, dated April 1, 2005).<br>> Boston Scientific Sterling Monorail PTA Balloon Dilatation<br>Catheter. This device was determined substantially equivalent by FDA<br>(ref. 510(k) number #K053118, dated December 16, 2005. | | |
| Device<br>description | The Cordis AMIIA PTA Balloon Dilatation Catheter is a catheter with a distal<br>DURALYNTM inflatable balloon. The catheter utilizes a Rapid Exchange<br>design, consisting of a single inflation lumen and a distal guide wire lumen.<br>The guide wire lumen begins at the distal tip and terminates at the guide wire<br>exit port. The guide wire exit port (hole) is approximately 25 cm from the<br>distal tip. The maximum guide wire diameter that may be used is printed on<br>the package label. The catheter tip is tapered to facilitate crossing of tight<br>lesions.<br>The proximal hub is used as a balloon inflation port. The balloon is inflated<br>by injecting diluted contrast medium through this hub. Two radiopaque<br>marker bands within the balloon indicate the dilating section of the balloon<br>and aid in balloon placement. The nominal balloon diameter and length are<br>printed on the identification band near the hub.<br>The working pressure range for the balloon is between the nominal pressure<br>and the rated burst pressure. All balloons distend to sizes above the nominal<br>size at pressures greater than the nominal pressure. Consult the compliance<br>table incorporated with the product, for diameters of the balloon at given<br>pressures. The design of this catheter does not incorporate a lumen for distal<br>dye injection.<br>The balloon catheter with a usable shaft length of 142 cm has two proximal<br>shaft markers (90 cm and 100 cm from the distal tip). Both indicate the<br>relative position of the catheter tip to the distal end of the guiding catheter.<br>An additional marker is located at the distal port exit notch and aids in<br>locating the guide wire exit. | | |
## Classification Name & Device Classification
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Classification Name: Percutaneous Catheter (21 CFR 870.1250) Classification: Class II FDA Classification Panel: Cardiovascular Product Code: LIT 1
{1}------------------------------------------------
# FDA 510(k) Notification
# Cordis AMIIA PTA Balloon Dilatation Catheter
{2}------------------------------------------------
### FDA 510(k) Notification Cordis AMIIA PTA Balloon Dilatation Catheter The Cordis AMIIA PTA Balloon Dilatation catheter is intended for Intended Use Percutaneous Transluminal Angioplasty in the peripheral vasculature, including iliac, femoral, ilio-femoral, popliteal, infra popliteal, renal, and carotid arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for post dilatation of balloon-expandable and self-expanding stents in the peripheral vasculature. The safety and effectiveness of the subject Cordis AMIIA PTA Balloon Safety and Dilatation Catheter has been demonstrated via data collected from non-Performance clinical design verification tests and analyses. No biocompatibility test was Data required, as the original device has not changed and there was no change in the vascular application of the device [circulating blood contact with limited duration (< 24h.)]. In summary, the subject Cordis AMIIA PTA Balloon Dilatation Catheter is, Substantial in our opinion, substantial equivalent to the predicate devices with respect to Equivalence intended use, materials, fundamental design and technology, sterility and operating principles. A statement of substantial equivalence to another product is required by 21 Substantial CFR 807.87 and relates only to whether the present product can be marketed Equivalence without prior reclassification or clinical approval. Statement The present submission is therefore not related to the coverage of any patent and is not to be interpreted as an admission or used as evidence in a patent infringement lawsuit. As the commissioner of the FDA stated: "A determination of substantial equivalence under the Federal Food, Drug and Cosmetic Act related to the fact that the product can be lawfully marketed without pre-market approval or reclassification. The determination is not intended to have any bearing whatsoever on the resolution of patent infringement suits." 42 Federal Register 42, 50 et seq. (1977).
{3}------------------------------------------------
#### DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus, which is a symbol of medicine and health. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" are arranged in a circular pattern around the caduceus.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAR 0 7 2007
Cordis Europa, N.V. c/o Mr. Harm Hovinga Senior Regulatory Affairs Associate Oosteinde 8 9301 LJ Roden The Netherlands
Re: K063563
Trade/Device Name: Cordis AMIIA PTA Balloon Dilatation Catheter Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: LIT Dated: February 8, 2007 Received: February 9, 2007
Dear Mr. Hovinga:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{4}------------------------------------------------
Page 2 - Mr. Harm Hovinga
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
R. buhnes
A Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
### FDA 510(k) Notification
#### Cordis AMIIA PTA Balloon Dilatation Catheter
#### Section 2: Intended Use Statement Page 1 of 1
510(k) Number (if known): K063563
Device Name:
Cordis AMIIA PTA Balloon Dilatation Catheter
#### Indications for Use Statement
The Cordis AMIIA PTA Balloon Dilatation catheter is intended for Percutaneous Transluminal Angioplasty in the peripheral vasculature, including iliac, femoral, ilio-femoral, popliteal, infra popliteal, renal, and carotid arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for post-dilatation of balloonexpandable and self-expanding stents in the peripheral vasculature.
Prescription Use:_ X
OR Over-The-Counter Use
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
uma R. Va. Lunes
rdiovascular Devices
(K) Number_